SCHEDULE: Versant Funds Trim Stake in LENZ Therapeutics
Beneficial Ownership Update
Versant Venture Capital funds have reduced their beneficial ownership in LENZ Therapeutics, Inc. through recent share sales totaling over $10 million.
Summary
- Versant Venture Capital VI, L.P. (Versant VI) sold a total of 175,679 shares of Common Stock in two transactions on August 15, 2025, and August 18, 2025.
- The August 15, 2025 sale by Versant VI involved 145,051 shares at $39.500 per share, yielding approximately $5,729,514.50.
- The August 18, 2025 sale by Versant VI involved 30,628 shares at a weighted average price of $38.5611 per share, yielding approximately $1,181,049.37.
- Versant Venture Capital VII, L.P. (Versant VII) sold a total of 85,034 shares of Common Stock in two transactions on August 15, 2025, and August 18, 2025.
- The August 15, 2025 sale by Versant VII involved 69,949 shares at $39.500 per share, yielding approximately $2,762,985.50.
- The August 18, 2025 sale by Versant VII involved 15,085 shares at a weighted average price of $38.5611 per share, yielding approximately $581,694.19.
- Following these sales, Versant VI beneficially owns 1,400,220 shares, representing 4.9% of the class.
- Versant Vantage II, L.P. beneficially owns 842,162 shares, representing 3.0% of the class.
- Versant VII beneficially owns 1,033,412 shares, representing 3.6% of the class, which includes 70,534 shares issuable upon warrant exercise.
Sentiment
Score: 4
Explanation: The reduction in beneficial ownership by a significant institutional investor, Versant Venture Capital, could be perceived as a slight negative signal regarding their long-term conviction in LENZ Therapeutics, although it may also represent portfolio rebalancing.
Negatives
- The reduction in beneficial ownership by significant institutional investors like Versant Venture Capital funds could be perceived negatively by the market, potentially signaling a decrease in their long-term conviction or a strategic rebalancing.
Future Outlook
NA
Industry Context
This filing primarily details changes in beneficial ownership by a specific investment group and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders may react negatively to a significant institutional investor reducing its stake, potentially leading to downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| July 9, 2021 | Original Schedule 13D filed by certain Reporting Persons. |
| November 17, 2023 | Amendment No. 1 to Schedule 13D filed. |
| March 25, 2024 | Amendment No. 2 to Schedule 13D filed. |
| November 8, 2024 | Amendment No. 3 to Schedule 13D filed. |
| June 12, 2025 | Amendment No. 4 to Schedule 13D filed. |
| June 24, 2025 | Amendment No. 5 to Schedule 13D filed. |
| July 14, 2025 | Amendment No. 6 to Schedule 13D filed. |
| July 24, 2025 | Date of Common Stock outstanding reported in the Issuer's quarterly report on Form 10-Q. |
| July 30, 2025 | Issuer's quarterly report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC. |
| August 15, 2025 | Versant VI and Versant VII sold shares of Common Stock. |
| August 18, 2025 | Versant VI and Versant VII sold additional shares of Common Stock, which is the event date requiring this filing. |
| August 20, 2025 | Date of signature for the Schedule 13D Amendment No. 7 filing. |
Recommendation
holdThe filing indicates a reduction in beneficial ownership by Versant Venture Capital funds through recent share sales. While this action by a significant investor could be interpreted as a slight negative signal or portfolio rebalancing, it does not provide sufficient new information about the company's fundamentals or future prospects to warrant a strong buy or sell recommendation. Investors should hold and monitor for further developments or company-specific news.
Keywords
LENZ Therapeutics, Versant Venture Capital, Schedule 13D, Share Sales, Beneficial Ownership, Biotechnology, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.